Track topics on Twitter Track topics that are important to you
PLYMOUTH, Minn., June 1, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on designing, developing and commercializing products for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the European launch of the XprESS™ LoProfile Multi-Sinus Dilation System. The XprESS LoProfile product is used by ENT (Ear, Nose and Throat) physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation.
Entellus will be exhibiting at the Congress of European ORL-HNS in Prague on June 7-11th. The Company will also be sponsoring a symposia led by Dr. David Roberts, Otorhinolaryngologist, Guy's University London entitled "Discussing Appropriate Intervention Strategies for Sinusitis." Dr. Peter Andrews, ENT Head and Neck Surgeon, The Royal National Throat, Nose and Ear Hospital and Royal Free Hospital, UK, with Dr. Paolo Castelnuovo, Professor of Otolaryngology, University of Insubria, Italy also participating.
Entellus recently established its UK subsidiary and plans to sell its products using a combination of direct sales representatives and a network of independent distributors who have proven experience and expertise in selling products into the ENT markets of European countries.
When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery (FESS). Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS.
"The XprESS LoProfile offers physicians a simple, yet highly effective method of opening up the sinus ostia whilst preserving the sinus mucosa," said Dr. David Roberts. "This technology potentially enables safe and earlier intervention during the course of sinus disease." Dr. Roberts recently performed the first procedure with the XprESS LoProfile device in Europe.
"We are very excited to bring our XprESS LoProfile Multi-Sinus Dilation System to the European market to help improve the outcome of patients suffering from chronic and recurrent sinusitis," said Robert White, President and Chief Executive Officer, Entellus Medical, Inc. "Entellus balloon sinus dilation technology has been available for use by ENT physicians in the U.S. since 2010 and we believe it is well suited for expansion into Europe to treat appropriately indicated patients. We estimate the number of adult chronic sinusitis patients undergoing FESS each year in Europe is between 300,000 and 350,000."
About Chronic Sinusitis and Balloon Sinus Dilation:
Chronic sinusitis affects millions worldwide. Chronic sinusitis has a negative impact on quality of life with chronic symptoms and effects including facial pain and pressure, headaches, fatigue, loss of smell, and sinus infections.
Surgical treatment of chronic sinusitis routinely involves cutting and removal of sinus mucosal tissue near the opening of a sinus. Use of sinus balloon technology preserves the natural sinus anatomy and enables effective treatment of sinusitis patients in the comfort and convenience of a physician's office. In-office balloon sinus dilation is a proven, effective alternative treatment to endoscopic sinus surgery and provides patients lasting relief at a lower cost than traditional sinus surgery.
About Entellus Medical:
Entellus Medical is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery, or FESS. Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. Entellus Medical currently markets its products in the United States, Europe and Canada and sells its products through a direct sales force in the United States and the UK.
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause the performance of the Entellus XprESS Ultra device or Entellus Medical's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the company's significant operating expenses incurred since inception and expected to incur in the future; its dependence on a limited number of products, including the XprESS family of multi-sinus products; physicians' willingness to change current practices and continue to adopt office-based balloon sinus dilation procedures; inability to maintain adequate levels of reimbursement for the procedures using the company's products; the impact of competition within the industry; the company's substantial dependence on a key license agreement; and the company's ability to establish and maintain intellectual property protection for its products or avoid claims of infringement. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found under the caption "Risk Factors" in the company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission, or SEC, and its other reports filed with the SEC. Entellus Medical undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause our views to change.
CONTACT: MEDIA CONTACT: Leigh Salvo 415-513-1281 email@example.com Entellus Medical, Inc.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...